GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CHRS
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Coherus BioSciences stock price took a fall of -6.98% on Thursday
(Updated on Apr 18, 2024)

Sell candidate since Apr 12, 2024 Loss -10.31% PDF

The Coherus BioSciences stock price fell by -6.98% on the last day (Thursday, 18th Apr 2024) from $2.15 to $2.00. During the last trading day the stock fluctuated 9.80% from a day low at $1.99 to a day high of $2.19. The price has fallen in 7 of the last 10 days and is down by -14.16% for this period. Volume has increased on the last day by 635 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $3.78 million.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.92 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -4.05% during the next 3 months and, with a 90% probability hold a price between $1.85 and $2.66 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CHRS Signals & Forecast

There are few to no technical positive signals at the moment. The Coherus BioSciences stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.23 and $2.31. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, April 08, 2024, and so far it has fallen -20.32%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Coherus BioSciences stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.195 between high and low, or 9.80%. For the last week, the stock has had daily average volatility of 6.73%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (CHRS) For The Upcoming Trading Day Of Friday 19th

For the upcoming trading day on Friday, 19th we expect Coherus BioSciences to open at $2.06, and during the day (based on 14 day Average True Range), to move between $1.84 and $2.16, which gives a possible trading interval of +/-$0.165 (+/-8.25%) up or down from last closing price. If Coherus BioSciences takes out the full calculated possible swing range there will be an estimated 16.49% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $2.30, some $0.300 (15.00%) from the current price of $2.00, our system finds the risk reward not very attractive.

Is Coherus BioSciences stock A Buy?

Coherus BioSciences holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.064 Sell Candidate Unchanged

Predicted Opening Price for Coherus BioSciences of Friday, April 19, 2024

Fair opening price April 19, 2024 Current price
$2.06 ( 2.92%) $2.00

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CHRS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.25 12.67 %
R2 2.18 8.94 %
R1 2.13 6.64 %
Current price: 2.00
Support S1 1.98 -0.81 %
S2 1.94 -3.11 %
S3 1.86 -6.83 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.40 20.00 %
R2 2.32 16.00 %
R1 2.30 15.00 %
Current price 2.00
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for Coherus BioSciences Stock and on which exchange is it traded?
The symbol for Coherus BioSciences is CHRS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Coherus BioSciences Stock?
Coherus BioSciences holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Coherus BioSciences Stock?
Coherus BioSciences Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Coherus BioSciences Stock.

What's the current price of Coherus BioSciences Stock?
As of the end of day on the 2024-04-18, the price of an Coherus BioSciences (CHRS) share was $2.00.

What is the 52-week high and low for Coherus BioSciences Stock?
The 52-week high for Coherus BioSciences Stock is $8.34 and the 52-week low is $1.44.

What is the market capitalization of Coherus BioSciences Stock?
As of the 2024-04-18, the market capitalization of Coherus BioSciences is 239.433M.

When is the next earnings date for Coherus BioSciences?
The upcoming earnings date for Coherus BioSciences is May 13, 2024.
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT